Literature DB >> 2282250

Growth factors and oncogenes in prostate cancer.

T C Thompson1.   

Abstract

Prostatic cancer is an increasing medical problem. Investigations of the biology of the prostate and the development of prostate cancer have shown that the prostate gland contains high levels of polypeptide growth factors, especially members of the fibroblast growth factor (FGF) and transforming growth factor (TGF)-beta family. Activated oncogenes and elevated proto-oncogene activities including ras and myc have been detected in human prostate cancer tissues, but there is no consensus as to the predominant genetic alterations involved in the progression of this disease. In vivo animal models have shown that relevant growth factors and oncogenes can induce both premalignant and malignant changes in prostate tissue. Additional experimental and clinical studies are needed to present a clearer molecular profile of this important malignancy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2282250

Source DB:  PubMed          Journal:  Cancer Cells        ISSN: 1042-2196


  14 in total

1.  Spontaneous but not experimental metastatic activities differentiate primary tumor-derived vs metastasis-derived mouse prostate cancer cell lines.

Authors:  S J Hall; T C Thompson
Journal:  Clin Exp Metastasis       Date:  1997-11       Impact factor: 5.150

2.  High dose intravenous oestrogen (fosfestrol) in the treatment of symptomatic, metastatic, hormone-refractory carcinoma of the prostate.

Authors:  M Ahmed; S Choksy; C P Chilton; K W Munson; J H Williams
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

Review 3.  Molecular biology of prostate cancer.

Authors:  X B Shi; P H Gumerlock; R W deVere White
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 4.  Transforming growth factor-beta and prostate cancer.

Authors:  M S Steiner
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

Review 5.  Regulation of prostate growth by fibroblast growth factors.

Authors:  M T Story
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

6.  Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer.

Authors:  Barbara Seliger; Robert Stoehr; Diana Handke; Anja Mueller; Soldano Ferrone; Bernd Wullich; Andrea Tannapfel; Ferdinand Hofstaedter; Arndt Hartmann
Journal:  Cancer Immunol Immunother       Date:  2009-10-07       Impact factor: 6.968

7.  Detection of prostate-specific antigen immunoreactivity in breast tumors.

Authors:  E P Diamandis; H Yu; D J Sutherland
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

8.  Epidermal growth factor receptor content in rat prostatic adenocarcinoma: effects of endocrine treatment.

Authors:  J E Damber; A Bergh; B Assarsson; M Gåfvels
Journal:  Urol Res       Date:  1995

9.  Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.

Authors:  P A Humphrey; X Zhu; R Zarnegar; P E Swanson; T L Ratliff; R T Vollmer; M L Day
Journal:  Am J Pathol       Date:  1995-08       Impact factor: 4.307

10.  Pathogenesis of prostate cancer and hormone refractory prostate cancer.

Authors:  J S Girling; H C Whitaker; I G Mills; D E Neal
Journal:  Indian J Urol       Date:  2007-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.